News Agency
The Times

First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal

  • Written by PR Newswire
First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical journal

HONG KONG, Aug. 26, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company committed to the research, development, manufacturing and commercialization of either first-in-class or best-in-class therapies, announced a review article featuring on Cadonilimab, a first-in-class PD-1/CTLA-4 bi-specific antibody developed by...

Read more: First approval of Cadonilimab (PD-1/CTLA-4 bispecific) published in Drugs, a peer-reviewed medical...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion